<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287335</url>
  </required_header>
  <id_info>
    <org_study_id>CLEAR-C 2018</org_study_id>
    <nct_id>NCT04287335</nct_id>
  </id_info>
  <brief_title>Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China</brief_title>
  <acronym>CLEAR-C</acronym>
  <official_title>Stool KRAS Mutation, BMP3/NDRG4 Methylation and FIT Panel Test for the Detection of Colorectal Advanced Neoplasia in High Risk Chinese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New Horizon Health Technology Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Mingze Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the diagnostic sensitivity and specificity of the newly
      developed multitarget FIT-DNA Colorectal Cancer (CRC) screening test (ColoClear) for
      detecting advanced neoplasia (including colorectal cancer and advanced adenomas) in high risk
      patients, using colonoscopy as the reference method. The secondary objective is to compare
      the screening performance of the multitarget FIT-DNA test with commercially available FIT
      (Fecal Immunochemical Test) assay in detecting advanced neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be carried out in 8 tier-3A hospitals throughout China. Patients who are at
      high risk of developing colorectal cancer and willing to conduct colonoscopy examination will
      be asked to collect stool sample prior to bowl preparation for multitarget FIT-DNA test and
      commercially available FIT assay. Colonoscopy and histopathologic examination are used as
      reference.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 8, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of the ColoClear screening test with comparison to colonoscopy</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination. The DNA test includes molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, plus a hemoglobin immunoassay. A logistic-regression algorithm incorporating all the above parameters was deployed to compute a single composite score, with values of 165 or more considered to be positive. The tests were processed independently of colonoscopy procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of the ColoClear screening test with comparison to FIT, with respect to advanced adenoma (AA) and CRC</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>A diagnostic colonoscopy procedure is the reference method. Lesions will be confirmed as malignant by histopathologic examination. The ColoClear and FIT test were performed on the same stool sample.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4758</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Adenomatous Polyps</condition>
  <condition>Adenoma</condition>
  <condition>Advanced Adenoma</condition>
  <arm_group>
    <arm_group_label>High risk CRC screening group</arm_group_label>
    <description>Prospective enrollment of subjects with pre-defined high risk factors for developing colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRC group</arm_group_label>
    <description>Retrospective enrollment of subjects with confirmed colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multitarget stool FIT-DNA test - ColoClear</intervention_name>
    <description>Multitarget stool FIT-DNA test</description>
    <arm_group_label>CRC group</arm_group_label>
    <arm_group_label>High risk CRC screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FIT</intervention_name>
    <description>fecal immunochemical test</description>
    <arm_group_label>CRC group</arm_group_label>
    <arm_group_label>High risk CRC screening group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colonoscopy</intervention_name>
    <description>diagnostic colonoscopy</description>
    <arm_group_label>CRC group</arm_group_label>
    <arm_group_label>High risk CRC screening group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      stool sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with high risk of developing CRC and patients with confirmed CRC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to provide written consent

          -  Able to provide stool sample

        For high risk CRC screening group:

          -  Scheduled for colonoscopy voluntarily or by physician prescription

          -  CRC high risk profile as defined below:

          -  History of FIT positivity

          -  Family history of CRC

          -  Any of two of the following clinical symptoms: chronic constipation/diarrhea, stool
             with mucous, chronic appendicitis, chronic bilary track diseases, mental stress

        For CRC group:

          -  Confirmed CRC patients

          -  No prior treatment with chemotherapy, radiotherapy, and prior to any surgical
             procedures

        Exclusion Criteria:

          -  Unwilling to provide stool samples

          -  FAP (familial adenomatous polyposis), Crohn's disease, ulcerative colitis

          -  Prior history of colonoscopy within the past 5 years and removal of lesions

          -  History of CRC

          -  other conditions deemed not suited for the study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kefeng Ding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ding Ke-Feng</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Adenomatous Polyps</keyword>
  <keyword>Adenoma</keyword>
  <keyword>Advanced adenoma</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <keyword>Glandular and Epithelial</keyword>
  <keyword>Neoplasms by Histologic Type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Adenomatous Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

